S-1: Silexion S-1: Public Offering & Nasdaq Compliance Plan

Silexion Therapeutics Corp files an S-1 for a best-efforts public offering of up to 832,177 ordinary shares and warrants, while addressing significant operating losses and Nasdaq listing compliance challenges.

Summary

• Silexion Therapeutics Corp, a clinical-stage oncology biotechnology company, is engaged in the discovery and development of proprietary treatments for KRAS-driven cancers using RNAi therapeutics.
• The company is offering up to 832,177 ordinary shares, along with Series A and Series B ordinary warrants, and pre-funded warrants, in a best-efforts public offering.
• The assumed public offering price is $7.21 per share and accompanying ordinary warrant, based on the Nasdaq closing price on September 2, 2025.
• For purchasers whose ownership would exceed 4.99% (or 9.99% by election), pre-funded warrants are offered at an assumed price of $7.2099, exercisable at $0.0001 per share.
• The Series A ordinary warrants expire in five years, and Series B ordinary warrants expire in 12 months from the Initial Exercise Date.
• Placement agent warrants for up to 58,252 ordinary shares (7.0% of the offering) will be issued, with an exercise price of 125% of the public offering price.
• The company estimates net proceeds of approximately $5.2 million from the maximum offering, which will be used to advance pre-clinical and clinical studies and for general corporate purposes.
• Silexion reported net losses of $4.2 million for the six months ended June 30, 2025, and $16.5 million for the year ended December 31, 2024.
• As of June 30, 2025, the accumulated deficit was $47.5 million, and cash and cash equivalents totaled $3.5 million.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• Silexion is addressing Nasdaq listing deficiencies related to Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS), and was transferred to the Nasdaq Capital Market on July 8, 2025.
• A compliance plan requires demonstrating at least $2.5 million in shareholders' equity by September 19, 2025, and maintaining compliance with Nasdaq rules by November 18, 2025.
• Two reverse share splits were effected: 1-for-9 on November 27, 2024, and 1-for-15 on July 28, 2025, to address bid price deficiencies and maintain Nasdaq listing.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, including recurring losses, a substantial accumulated deficit, and a going concern warning from auditors. While the scientific approach is promising and clinical trials are progressing, the immediate financial outlook and Nasdaq compliance challenges present high risks and uncertainty for investors. The capital raise is a necessity rather than a sign of strength, and the best-efforts nature adds further uncertainty.

Positives

• The lead product candidate, SIL204, is a second-generation siRNA targeting KRAS-driven cancers, an oncogene central to many cancer types like pancreatic, colorectal, and lung.
• Silexion's approach of silencing the KRAS oncogene upstream of protein production is differentiated from existing inhibitors.
• A Phase 2 clinical trial with the first-generation product (siG12D-LODER) showed a numerical advantage of 9.3 months in overall survival for KRAS G12D/V patients when combined with standard of care chemotherapy.
• Pre-clinical studies for SIL204 demonstrated broad silencing activity across various KRAS mutations (G12D, G12V, G12C, G12R, Q61H, G13D) and synergistic effects with standard chemotherapeutic agents.
• SIL204 showed significant efficacy in mouse metastatic pancreatic orthotopic models, reducing overall bioluminescence by 70% in AsPC-1 tumors and halting growth in Panc-1 tumors.
• In vivo studies indicated SIL204 treatment significantly reduced metastatic spread to secondary organs.
• In silico analyses suggest high specificity for SIL204 with strong on-target binding and minimal off-target effects, reducing the risk of systemic side effects.
• The Federal Institute for Drugs and Medical Devices in Germany (BfArM) has agreed in principle to the planned design of the Phase 2/3 trial for SIL204.
• The company plans to apply for Orphan Drug Designation in both the U.S. and EU for SIL204, which could provide market exclusivity and other benefits.
• The company has a world-class clinical advisory board to guide market understanding and strategic alliances.

Negatives

• The company has incurred significant losses since inception, with net losses of $4.2 million for the six months ended June 30, 2025, and $16.5 million for the year ended December 31, 2024.
• An accumulated deficit of $47.5 million as of June 30, 2025, indicates a history of unprofitability.
• The independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• The company has never generated revenue from product sales and does not anticipate doing so for the foreseeable future.
• Substantial additional funding is required for product development and commercialization, which may not be available on acceptable terms or at all, leading to potential dilution for shareholders.
• The company faces intense competition from major pharmaceutical and biotechnology companies with greater resources and more established products.
• The RNAi therapeutic approach for oncology is unproven, and there are potential challenges related to off-target effects, interferon response, and drug delivery.
• The company has no experience producing product candidates at commercial levels and lacks a marketing and sales organization.
• Nasdaq listing deficiencies related to Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS) led to transfer to the Nasdaq Capital Market and ongoing compliance conditions.
• The best-efforts nature of the current offering means there is no guarantee of raising sufficient capital to meet business goals, potentially leading to limited working capital.
• The market may not be receptive to product candidates based on a novel therapeutic modality, and insurance coverage and reimbursement status for newly-approved products are uncertain.
• The company's operations are centered in Israel, exposing it to risks from political instability and armed conflicts in the Middle East, which could disrupt business.

Risks

• We are a development-stage company with a limited operating history and have incurred significant losses since inception, anticipating continued losses for the foreseeable future.
• We have never generated any revenue from product sales and may never be profitable, with future revenue dependent on successful development and regulatory approval of product candidates.
• We will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to shareholders.
• Our independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.
• The RNAi therapeutic approach for oncology is unproven and may never lead to marketable products, with limited data and no conclusive evidence of drug-like properties in siRNAs.
• We are heavily dependent on the success of our product candidates, which are in early stages of preclinical or clinical development, and cannot assure regulatory approval.
• Difficulty enrolling patients in clinical studies could delay or prevent clinical studies of our product candidates, especially for rare diseases like pancreatic cancer.
• Our product candidates and their administration may cause undesirable side effects or have other properties that could delay or prevent regulatory approval or limit commercialization.
• Even if regulatory approval is obtained, our products will remain subject to regulatory scrutiny, and failure to comply with ongoing requirements could lead to sanctions or withdrawal of approval.
• We are subject to a multitude of manufacturing risks, including contamination, equipment failure, and supply disruptions, which could increase costs and limit supply.
• Reliance on third parties to conduct preclinical and clinical studies and manufacture raw materials entails risks if they fail to meet contractual duties, deadlines, or regulatory requirements.
• If market opportunities for our product candidates are smaller than believed, revenue may be adversely affected, particularly for small target patient populations.
• We do not have experience producing product candidates at commercial levels and may not achieve necessary regulatory approvals or consistent supply.
• Intense competition and rapid technological change from other companies developing similar or more effective therapies could adversely affect our ability to commercialize.
• We currently have no marketing and sales organization and may be unable to establish one or enter into favorable third-party agreements.
• The market may not be receptive to our product candidates based on a novel therapeutic modality, and insurance coverage and reimbursement status are uncertain.
• Failure to obtain and maintain effective patent rights for product candidates could impair our ability to compete effectively.
• We may not have sufficient patent terms to effectively protect our products and business, and patent law changes could increase uncertainties and costs.
• Intellectual property rights of third parties could adversely affect our ability to commercialize, potentially requiring costly litigation or licenses.
• We may be involved in lawsuits to protect or enforce patents, which could be expensive, time-consuming, and unsuccessful.
• Claims challenging inventorship of patents or wrongful use/disclosure of confidential information could lead to loss of intellectual property rights or personnel.
• Protecting intellectual property rights globally is expensive and laws in some foreign countries may not protect rights to the same extent as in the U.S.
• Loss of key personnel or inability to attract and retain additional employees would negatively affect our business.
• Computer system failures, cyberattacks, or cybersecurity deficiencies could materially affect our results, especially given reliance on IT systems and remote work.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization of approved products.
• Inability to successfully identify and execute strategic alliances or manage acquisitions/dispositions could impact operations.
• Conditions in the Middle East and Israel, where our executive offices and R&D facilities are located, may harm operations, including potential cyberattacks and political instability.
• Difficulty enforcing U.S. judgments or asserting U.S. securities law claims in Israel due to incorporation under Cayman Islands law.
• Economic substance legislation of the Cayman Islands may adversely impact operations if compliance requirements are not met.
• The best-efforts structure of this offering means we may sell fewer than all securities, receiving significantly less net proceeds and potentially insufficient working capital.
• Management will have broad discretion over the use of net proceeds and may not use them effectively.
• New investors will experience immediate dilution in the book value per share.
• There is no public market for the ordinary warrants or pre-funded warrants being offered, limiting their liquidity.
• The ordinary warrants may not have any value if the market price does not exceed the exercise price or if shareholder approval for exercise is not obtained.
• Failure to maintain Nasdaq continued listing requirements could lead to delisting, severely limiting trading and market liquidity.
• The price of our ordinary shares and warrants may be volatile, unrelated to operating performance, and subject to broad market fluctuations.
• Substantial issuance of ordinary shares under the White Lion Purchase Agreement or A&R Sponsor Promissory Note could cause significant dilution and depress share price.
• No current plans to pay cash dividends means investors may not receive return unless shares are sold for a price greater than paid.
• Extreme price volatility following reverse share splits may make it difficult for investors to assess value.
• PFIC status could result in adverse U.S. federal income tax consequences to U.S. Holders.
• U.S. Holders owning at least 10% of shares may be subject to adverse U.S. federal income tax consequences as a United States shareholder of a controlled foreign corporation (CFC).

Future Outlook

The company plans to initiate toxicology studies for SIL204 in 2025, followed by regulatory submissions in Q4 2025 (Israeli Ministry of Health) and Q1 2026 (BfArM) to initiate a Phase 2/3 trial in H1 2026. They also expect to apply for Orphan Drug Designation in the U.S. and EU in 2026 and are planning preclinical studies to expand the pipeline for additional indications and combination uses of SIL204. The company anticipates continued significant expenses and operating losses for the foreseeable future and will require substantial additional capital to finance operations, expand the business, and pursue regulatory approvals.

Management Comments

• Our technology works by inducing the tumor cells to destroy the messenger (mRNA) between the oncogene and the tumor cells protein manufacturing apparatus.
• We believe this approach has various important clinical advantages.
• We are further expecting improved overall survival results with our second generation product SIL204.
• At this time, we are focused on the further development of the core siRNA technology, SIL204, and its clinical development.
• We believe the optimization of our siRNA and moving to the second generation product allows for more of a personalized medicine approach to the dosing, allowing the siRNA dose to be adjusted to the tumor size.
• Our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the date of this registration statement without additional financing, and as a result, there is substantial doubt about our ability to continue as a going concern.

Industry Context

Silexion operates in the intensely competitive and rapidly evolving biotechnology and pharmaceutical industries, specifically targeting the oncology sector with a focus on KRAS-driven cancers. While KRAS is a highly sought-after therapeutic target, Silexion's RNAi technology offers a differentiated 'upstream' approach by silencing the oncogene to prevent protein production, contrasting with existing inhibitors that act after protein function. The market for RNAi therapeutics is emerging, with few approved drugs, primarily in non-oncological indications. The company faces competition from major pharmaceutical players and smaller biotechs developing both KRAS inhibitors and other cancer treatments, including novel small molecules, cell-based therapies, and traditional chemotherapy. The success of RNAi in oncology remains unproven, and the company must overcome skepticism and challenges related to drug delivery and off-target effects.

Comparison to Industry Standards

• Silexion's approach to silencing the KRAS oncogene is distinct from competitors like Bristol-Myers Squibb (Mirati Therapeutics), Amgen, AstraZeneca (Usynova), Boehringer, and Gilead, which are developing inhibitors that act after the KRAS protein is already functioning. Silexion aims to prevent the protein's production entirely.
• The company's first-generation siRNA product, siG12D-LODER, showed a numerical overall survival advantage of 9.3 months in a Phase 2 trial for LAPC patients with KRAS G12D/V mutations, which is a positive indicator compared to standard of care chemotherapy alone, though the trial was not powered for statistical significance.
• The safety profile of Loder treatment in Phase 2 was well tolerated, with adverse events primarily related to the endoscopic ultrasound procedure, consistent with good safety profiles of marketed siRNA products in other indications.
• SIL204, the second-generation siRNA, demonstrates broad silencing activity across multiple KRAS mutations (G12D, G12V, G12C, G12R, Q61H, G13D) at sub-nanomolar concentrations, maintaining and expanding upon the activity of the first-generation product.
• Pre-clinical data for SIL204 shows synergistic effects with standard chemotherapeutic agents like fluorouracil, irinotecan, and gemcitabine, which is crucial for its intended first-line treatment use in pancreatic cancer, aligning with current gold-standard treatments like FOLFIRINOX.
• The planned Phase 2/3 trial design for SIL204 has received in-principle agreement from BfArM in Germany, indicating a potentially robust and regulatorily acceptable pathway for a pivotal trial, which is a critical step in drug development.
• The company's focus on intratumoral and subcutaneous delivery for pancreatic cancer aims to overcome the strong barrier surrounding these tumors, a known challenge for many systemic treatments in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• Ilan Hadar (CEO and Chairman) and Mirit Horenshtein Hadar (CFO and Secretary) are married. Their employment agreements provide for annual base salaries of $357,820 and $234,210, respectively, plus customary benefits.
• Ilan Hadar was granted 956 options to purchase New Silexion ordinary shares, and Mirit Horenshtein Hadar was granted 420 RSUs, with vesting accelerated upon the Business Combination.
• Dr. Mitchell Shirvan (Chief Scientific and Development Officer) was granted 478 options and 981 RSUs, with vesting accelerated upon the Business Combination.
• The company entered into indemnification agreements with each of its directors and executive officers.
• Guangzhou Sino-Israel Bio-Industry Investment Fund I (GIBF), which beneficially owned 20.3% of issued share capital after the Business Combination, transferred its 49% interest in the Chinese subsidiary to New Silexion in exchange for 13,599 New Silexion ordinary shares.
• GIBF also received an additional 1,122 ordinary shares upon conversion of RSUs.
• Avner Lushi and Shlomo Noy, directors, share voting and investment power over the 14,721 ordinary shares beneficially owned by GIBF.
• Greenstar, LP, an affiliate of the Moringa Sponsor, purchased 1,482 Moringa ordinary shares for $2.0 million in a PIPE financing, which converted into New Silexion ordinary shares.
• The company issued an Amended and Restated Sponsor Promissory Note for $3.433 million to Moringa Sponsor, LP, convertible into ordinary shares.
• An Amended and Restated Registration Rights and Lock-Up Agreement was entered into with Moringa Sponsor, PIPE Investor, and other shareholders, granting registration rights and imposing lock-up periods (now expired).

Stakeholder Impact

• **Shareholders:** Existing shareholders face significant dilution from the current public offering and potential future capital raises. The company's going concern status and Nasdaq compliance issues pose substantial risks to share price and liquidity. The reverse share splits have also contributed to price volatility.
• **Employees:** The company's ability to continue as a going concern directly impacts job security. Equity incentive plans are in place to attract and retain talent, but the value of these awards is tied to the company's volatile share price.
• **Customers (future):** The successful development and commercialization of SIL204 could offer a novel treatment option for KRAS-driven cancers, particularly pancreatic cancer, potentially benefiting patients.
• **Creditors:** The company's financial instability and need for additional funding raise concerns about its ability to meet debt obligations, as highlighted by the going concern warning.
• **Regulatory Bodies:** The company is actively engaging with regulatory authorities (e.g., BfArM, FDA) for clinical trial design and potential Orphan Drug Designation, indicating adherence to regulatory pathways despite financial challenges.

Next Steps

• Initiate toxicology studies of SIL204 in 2025.
• Submit regulatory filings to the Israeli Ministry of Health in Q4 2025 for the Phase 2/3 trial.
• Submit regulatory filings to BfArM in Q1 2026 for the Phase 2/3 trial.
• Initiate the Phase 2/3 clinical trial for SIL204 in H1 2026.
• Apply for Orphan Drug Designation in the U.S. and EU in 2026.
• Conduct preclinical studies to expand the pipeline for additional indications and combination uses of SIL204.
• Demonstrate restoration of compliance with Nasdaq's $2.5 million shareholders' equity requirement by September 19, 2025.
• Maintain compliance with all Nasdaq listing rules on or before November 18, 2025, or submit a new compliance plan for review by the Nasdaq hearings panel.
• Seek shareholder approval for the issuance of ordinary shares upon exercise of ordinary warrants, if Pricing Conditions are not met, with meetings every 90 days until approval or warrants are no longer outstanding.

Key Dates

Keywords

Silexion Therapeutics, SEC Filing, S-1 Registration, Public Offering, Biotechnology, Oncology, KRAS Cancer, RNAi Therapeutics, SIL204, Pancreatic Cancer, Clinical Stage, Nasdaq Capital Market, Warrants, Pre-funded Warrants, Share Dilution, Going Concern, Regulatory Approval, Clinical Trials, Drug Development, Biopharmaceutical, Corporate Finance, Risk Factors